COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

A Study of LY3039478 in Japanese Participants With Advanced Solid Tumors

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02836600
Recruitment Status : Active, not recruiting
First Posted : July 19, 2016
Last Update Posted : September 18, 2020
Information provided by (Responsible Party):
Eli Lilly and Company

Brief Summary:
The purpose of this study is to evaluate the tolerability of the study drug LY3039478 in Japanese participants with advanced solid tumors.

Condition or disease Intervention/treatment Phase
Advanced Solid Tumor Drug: LY3039478 Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 12 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 1 Study of LY3039478 in Japanese Patients With Advanced Solid Tumors
Actual Study Start Date : September 9, 2016
Actual Primary Completion Date : July 5, 2019
Estimated Study Completion Date : November 30, 2021

Arm Intervention/treatment
Experimental: LY3039478
LY3039478 given orally TIW (3 times per week) in 28 day cycles. Treatment will continue until disease progression, development of unacceptable toxicity, or any other discontinuation criteria are met.
Drug: LY3039478
Administered orally

Primary Outcome Measures :
  1. Number of Participants with LY3039478 Dose-Limiting Toxicities (DLTs) [ Time Frame: Cycle 1 (28 days) ]

Secondary Outcome Measures :
  1. Pharmacokinetics (PK): Maximum Concentration (Cmax) of LY3039478 [ Time Frame: Cycle 1 Day 1 through Cycle 2 Day 1 (28 day cycles) ]
  2. PK: Area Under the Curve (AUC) of LY3039478 [ Time Frame: Cycle 1 Day 1 through Cycle 2 Day 1 (28 day cycles) ]
  3. Overall Response Rate (ORR): Percentage of Participants Who Achieve Complete Response (CR) or Partial Response (PR) [ Time Frame: Baseline through Disease Progression or Death (estimated at up to 9 months) ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   20 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Histological or cytological evidence of a diagnosis of solid tumor that is advanced and/or metastatic.
  • In the judgment of the investigator, participants must be appropriate candidates for experimental therapy after available standard therapies have failed or for whom standard therapy is not appropriate.
  • Performance status of ≤1 on the Eastern Cooperative Oncology Group (ECOG) scale.
  • Adequate organ function, including hematologic, hepatic, and renal.
  • Estimated life expectancy of ≥12 weeks.

Exclusion Criteria:

  • Received previous therapy for cancer within 14 or 21 days of the initial dose of study drug for a nonmyelosuppressive or myelosuppressive agents, respectively.
  • Have serious preexisting medical conditions.
  • Have current or recent (within 3 months of study drug administration) gastrointestinal disease with chronic or intermittent diarrhea.
  • Have an active bacterial, fungal, and/or known viral infection.
  • Have known acute or chronic leukemia or current hematologic malignancies that may affect the interpretation of results.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02836600

Layout table for location information
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Kashiwa, Chiba, Japan, 277 8577
Sponsors and Collaborators
Eli Lilly and Company
Layout table for investigator information
Study Director: Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST) Eli Lilly and Company
Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Eli Lilly and Company Identifier: NCT02836600    
Other Study ID Numbers: 16191
I6F-JE-JJCC ( Other Identifier: Eli Lilly and Company )
First Posted: July 19, 2016    Key Record Dates
Last Update Posted: September 18, 2020
Last Verified: September 15, 2020
Keywords provided by Eli Lilly and Company:
notch inhibitor
Additional relevant MeSH terms:
Layout table for MeSH terms